Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Eder

Showing results (31-40 of 117) with videos related to

Pageof 12
Sort By:
Cardiovascular Research|November 30, 2006
Phospholipase C-dependent control of cardiac calcium homeostasis involves a TRPC3-NCX1 signaling complexP Eder, D Probst, C Rosker, et al.
Seminars in Oncology|February 1, 1990
Preclinical studies relating to the use of thiotepa in the high-dose setting alone and in combinationB A Teicher, S A Holden, J P Eder, et al.
The Lancet. Oncology|March 3, 2022
Yale Precision Medicine Tumor Board: reawakening the guardian of the genomeMichael J Grant, Karin E Finberg, Zenta Walther, et al.
The Lancet. Oncology|January 6, 2018
Introduction to the Yale Precision Medicine Tumor BoardMichael Cecchini, Zenta Walther, Jeffrey L Sklar, et al.
The Lancet. Oncology|September 20, 2020
Yale Cancer Center Precision Medicine Tumor Board: new technology, new drugs, and the value of repeat testingNavid Hafez, Zenta Walther, Joseph P Eder, et al.
Clinical Science (London, England : 1979)|November 1, 1989
Endogenous digoxin-like immunoreactive factor and digitalis-like factor associated with the hypertension of patients receiving multiple alkylating agents as part of autologous bone marrow transplantationS W Graves, J P Eder, S M Schryber, et al.
Elife|September 13, 2022
BRCA2 BRC missense variants disrupt RAD51-dependent DNA repairJudit Jimenez-Sainz, Joshua Mathew, Gemma Moore, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1993
Modulation of antitumor alkylating agents by novobiocin, topotecan, and lonidamineG N Schwartz, B A Teicher, J P Eder, et al.
The Lancet. Oncology|January 6, 2018
Yale Cancer Center Precision Medicine Tumor Board: two patients, one targeted therapy, different outcomesMichael Cecchini, Zenta Walther, Jeffrey L Sklar, et al.
Cancer Chemotherapy and Pharmacology|September 23, 1998
Sequence effect of irinotecan (CPT-11) and topoisomerase II inhibitors in vivoJ P Eder, V Chan, J Wong, et al.
Pageof 12

Showing results (31-40 of 117) with videos related to

Sort By:
Pageof 12
Cardiovascular Research|November 30, 2006
Phospholipase C-dependent control of cardiac calcium homeostasis involves a TRPC3-NCX1 signaling complexP Eder, D Probst, C Rosker, et al.
Seminars in Oncology|February 1, 1990
Preclinical studies relating to the use of thiotepa in the high-dose setting alone and in combinationB A Teicher, S A Holden, J P Eder, et al.
The Lancet. Oncology|March 3, 2022
Yale Precision Medicine Tumor Board: reawakening the guardian of the genomeMichael J Grant, Karin E Finberg, Zenta Walther, et al.
The Lancet. Oncology|January 6, 2018
Introduction to the Yale Precision Medicine Tumor BoardMichael Cecchini, Zenta Walther, Jeffrey L Sklar, et al.
The Lancet. Oncology|September 20, 2020
Yale Cancer Center Precision Medicine Tumor Board: new technology, new drugs, and the value of repeat testingNavid Hafez, Zenta Walther, Joseph P Eder, et al.
Clinical Science (London, England : 1979)|November 1, 1989
Endogenous digoxin-like immunoreactive factor and digitalis-like factor associated with the hypertension of patients receiving multiple alkylating agents as part of autologous bone marrow transplantationS W Graves, J P Eder, S M Schryber, et al.
Elife|September 13, 2022
BRCA2 BRC missense variants disrupt RAD51-dependent DNA repairJudit Jimenez-Sainz, Joshua Mathew, Gemma Moore, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1993
Modulation of antitumor alkylating agents by novobiocin, topotecan, and lonidamineG N Schwartz, B A Teicher, J P Eder, et al.
The Lancet. Oncology|January 6, 2018
Yale Cancer Center Precision Medicine Tumor Board: two patients, one targeted therapy, different outcomesMichael Cecchini, Zenta Walther, Jeffrey L Sklar, et al.
Cancer Chemotherapy and Pharmacology|September 23, 1998
Sequence effect of irinotecan (CPT-11) and topoisomerase II inhibitors in vivoJ P Eder, V Chan, J Wong, et al.
Pageof 12